Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer's vaccine portfolio includes Prevnar 13 (pneumococcal conjugate), Trumenba (meningococcal serogroup B), and a longstanding tickborne disease research…
Valneva SE today announced a collaboration with Pfizer Inc. to co-develop and commercialize VLA15, Valneva's Lyme disease vaccine candidate currently in Phase…
Pfizer and Valneva reported positive pediatric Phase 2 data for VLA15, demonstrating immunogenicity and safety supportive of pivotal Phase 3 enrollment in…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Pfizer and Valneva entered a collaboration to co-develop and commercialize VLA15, the only active Lyme disease vaccine candidate in clinical development. Valneva received $130M upfront, $35M development milestones, $143M early commercial milestones, plus 19% tiered royalties on sales. Pfizer led late-stage development and commercialization globally; Valneva funded 30% of shared development costs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Valneva SE (this deal) | 2020 | $308M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Infectious Disease deals